Raymond James Financial reiterated their buy rating on shares of Juno Therapeutics (NASDAQ:JUNO) in a research report released on Monday morning.

A number of other brokerages have also recently weighed in on JUNO. Wedbush upgraded shares of Juno Therapeutics from a neutral rating to an outperform rating and set a $42.00 price objective on the stock in a research note on Tuesday, August 29th. Wells Fargo & Company restated an outperform rating and set a $54.00 price objective (up from $35.00) on shares of Juno Therapeutics in a research note on Tuesday, September 5th. Standpoint Research restated a reduce rating on shares of Juno Therapeutics in a research note on Thursday, August 31st. Goldman Sachs Group restated a neutral rating and set a $44.00 price objective on shares of Juno Therapeutics in a research note on Friday, October 6th. Finally, Zacks Investment Research cut shares of Juno Therapeutics from a hold rating to a sell rating in a research note on Monday, August 28th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the stock. The company currently has an average rating of Hold and an average price target of $45.48.

Shares of Juno Therapeutics (NASDAQ JUNO) traded up $1.66 during midday trading on Monday, hitting $47.41. 4,304,600 shares of the company were exchanged, compared to its average volume of 2,083,050. Juno Therapeutics has a fifty-two week low of $17.52 and a fifty-two week high of $63.45. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01.

Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The business had revenue of $44.80 million for the quarter, compared to analysts’ expectations of $18.12 million. During the same period in the previous year, the business earned ($0.57) earnings per share. The company’s revenue was up 115.4% on a year-over-year basis. analysts predict that Juno Therapeutics will post -4.02 earnings per share for the current fiscal year.

In other Juno Therapeutics news, insider Sunil Agarwal sold 7,285 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $44.76, for a total value of $326,076.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Robert Azelby sold 6,666 shares of the business’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $54.95, for a total transaction of $366,296.70. Following the completion of the sale, the executive vice president now owns 79,998 shares in the company, valued at $4,395,890.10. The disclosure for this sale can be found here. 15.08% of the stock is currently owned by insiders.

Institutional investors have recently modified their holdings of the business. Advisor Group Inc. increased its stake in Juno Therapeutics by 141.1% in the 3rd quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 1,439 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Juno Therapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 228 shares in the last quarter. Pacad Investment Ltd. purchased a new position in Juno Therapeutics in the 2nd quarter worth about $105,000. Bronfman E.L. Rothschild L.P. increased its stake in Juno Therapeutics by 27,376.9% in the 3rd quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 3,559 shares in the last quarter. Finally, QS Investors LLC purchased a new position in Juno Therapeutics in the 2nd quarter worth about $135,000. Hedge funds and other institutional investors own 70.37% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.watchlistnews.com/juno-therapeutics-juno-earns-buy-rating-from-raymond-james-financial/1763760.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.